

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Sincere Pharmaceutical Group Limited**

**先聲藥業集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 2096)**

**VOLUNTARY ANNOUNCEMENT  
IN RELATION TO THE CLINICAL TRIAL APPROVAL  
FOR SIM0272 ISSUED BY  
THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION**

This announcement is made by Sincere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Group.

The board (the “**Board**”) of directors (“**Directors**”, and each a “**Director**”) of the Company is pleased to announce that, on March 21, 2022, the anti-tumor oral protein arginine methyltransferase 5 (PRMT5) inhibitor SIM0272 (Product Code: SCR-6920) self-developed by the Group has obtained the Clinical Trial Approval issued by the National Medical Products Administration (國家藥品監督管理局), which is intended to be used in the clinical trial for the treatment of advanced malignant tumors.

**ABOUT SIM0272**

SIM0272 is an oral protein arginine methyltransferase 5 (PRMT5) inhibitor self-developed by the Group for the “synthetic lethal” mechanism. PRMT5 is over-expressed in many cancers, such as lung cancer, breast cancer, gastric cancer, colorectal cancer, ovarian cancer, leukemia and lymphoma, and is associated with most cancer progression and prognosis. It plays an important role in the formation and evolution of tumor. Preclinical studies have shown that SIM0272 has strong inhibitory activity and high selectivity for PRMT5. SIMP0272 also shows the proliferation inhibitory activity of a variety of hematoma and solid tumor cells in vitro, and a single drug can significantly inhibit the tumor growth in multiple mouse CDX models. At the same time, it has good cross-species pharmacokinetic properties, good safety and broad therapeutic treatment window.

## **ABOUT THE COMPANY**

The Company is a company engaged in the R&D, production and commercialization of pharmaceuticals with the national key laboratory of translational medicine and innovative pharmaceuticals. The Company has a diversified product portfolio in strategically focused therapeutic areas, including (i) oncology, (ii) central nervous system diseases and (iii) autoimmune diseases, with leading positions in their respective therapeutic segments and/or established track record. The Company continues to source innovative therapies globally and established strategic partnership with several multinational companies.

By order of the Board  
**Sincere Pharmaceutical Group Limited**  
**Mr. Ren Jinsheng**  
*Chairman and Chief Executive Officer*

Hong Kong, March 22, 2022

*As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. WAN Yushan and Mr. TANG Renhong as the executive Directors; Mr. ZHAO John Huan as the non-executive Director; and Mr. SONG Ruilin, Mr. WANG Jianguo and Mr. WANG Xinhua as the independent non-executive Directors.*